MONITORING THE COMPARATIVE SAFETY OF SGLT2I VS GLP-1 RA IN OLDER ADULTS WITH TYPE 2 DIABETES BY FRAILTY STATUS

被引：0
|
作者：
Kutz, Alexander [1 ]
Patorno, Elisabetta [2 ,3 ]
Gopalakrishnan, Chandrasekar [2 ,3 ]
Kim, Dae [4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Hebrew SeniorLife, Boston, MA USA
来源：
INNOVATION IN AGING | 2021年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [31] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
    Schernthaner, Guntram
    Shehadeh, Naim
    Ametov, Alexander S.
    Bazarova, Anna V.
    Ebrahimi, Fahim
    Fasching, Peter
    Janez, Andrej
    Kempler, Peter
    Konrade, Ilze
    Lalic, Nebojsa M.
    Mankovsky, Boris
    Martinka, Emil
    Rahelic, Dario
    Serafinceanu, Cristian
    Skrha, Jan
    Tankova, Tsvetalina
    Visockiene, Zydrune
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [32] Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
    Morton, Jedidiah, I
    Marquina, Clara
    Shaw, Jonathan E.
    Liew, Danny
    Polkinghorne, Kevan R.
    Ademi, Zanfina
    Magliano, Dianna J.
    DIABETOLOGIA, 2023, 66 (04) : 642 - 656
  • [33] Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
    Jedidiah I. Morton
    Clara Marquina
    Jonathan E. Shaw
    Danny Liew
    Kevan R. Polkinghorne
    Zanfina Ademi
    Dianna J. Magliano
    Diabetologia, 2023, 66 : 642 - 656
  • [34] Initiation of SGLT2i Versus GLP1-RA and the Risk of Chronic Kidney Disease in Persons with Type 2 Diabetes Mellitus
    Jensen, Simon K.
    Heide-Jorgensen, Uffe
    Andersen, Ina T.
    Thomsen, Reimar W. W.
    Christiansen, Christian Fynbo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 87 - 87
  • [35] Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
    Guntram Schernthaner
    Naim Shehadeh
    Alexander S. Ametov
    Anna V. Bazarova
    Fahim Ebrahimi
    Peter Fasching
    Andrej Janež
    Péter Kempler
    Ilze Konrāde
    Nebojša M. Lalić
    Boris Mankovsky
    Emil Martinka
    Dario Rahelić
    Cristian Serafinceanu
    Jan Škrha
    Tsvetalina Tankova
    Žydrūnė Visockienė
    Cardiovascular Diabetology, 19
  • [36] GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
    Pablo, Aschner
    Evelyn, Blanc
    Claudia, Folino
    Yanina, Morosan A.
    CURRENT HYPERTENSION REVIEWS, 2021, 17 (02) : 149 - 158
  • [37] Extraglycemic Effects of SGLT2i/GLP1-ra: A Topic Update
    Alam, Uazman
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 826 - 827
  • [38] Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
    Michele Correale
    Olga Lamacchia
    Michele Ciccarelli
    Giuseppe Dattilo
    Lucia Tricarico
    Natale Daniele Brunetti
    Heart Failure Reviews, 2023, 28 : 733 - 744
  • [39] Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
    Correale, Michele
    Lamacchia, Olga
    Ciccarelli, Michele
    Dattilo, Giuseppe
    Tricarico, Lucia
    Brunetti, Natale Daniele
    HEART FAILURE REVIEWS, 2023, 28 (03) : 733 - 744
  • [40] Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
    Kutz, Alexander
    Kim, Dae Hyun
    Wexler, Deborah J.
    Liu, Jun
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (11) : 2004 - 2014
12345